Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
Childhood obstructive sleep apnoea is a condition characterized by loud snoring and disrupted sleep due to airway blockage, which can lead to daytime behavioral issues and metabol…
Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-…